Supporting Information:

"Catch and Release": A Variation of the Archetypal Nucleotidyl

Transfer Reaction

Brinda Selvaraj^{†⊥}, Seda Kocaman^{‡⊥}, Maria Trifas[†], Engin H. Serpersu^{*‡§} and Matthew J. Cuneo^{*}

[†]Neutron Sciences Directorate, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States [‡]The Department of Biochemistry and Cellular and Molecular Biology, The University of Tennessee, 1311 Cumberland Ave, Knoxville, Tennessee 37916, United States

[§]National Science Foundation, 2415 Eisenhower Avenue, Alexandria, Virginia 22314, United States

^{II}Department of Structural Biology, 262 Danny Thomas Pl, St. Jude Children's Research Hospital, Memphis, Terrasease 28105, United States

Tennessee 38105, United States

[⊥]These authors contributed equally to this work.

* Correspondence to: Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA, E-mail: matt.cuneo@stjude.org. Engin H. Serpersu, Department of Biochemistry and Cellular and Molecular Biology, The University of Tennessee, Knoxville, TN 37916; E-mail: serpersu@utk.edu and National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314. E-mail: eserpers@nsf.gov.

Contents:

Table S1. Data collection statistics of wild type and T130K ANT4'.

Table S2. Data collection statistics of T130K/E52D ANT4'.

Figure S5. Additional adenylated neomycin in ANT4' structure.

Figure S6. ITC based dissociation constants (Kd) for T130K and T130K/E52D ANT4'.

Figure S1. Two classes of aminoglycoside antibiotics.

Figure S2. Polder omit maps of ANT4' ligands.

Figure S3. LigPlot+ interaction analysis of T130K ANT4' ligands.

Figure S4. LigPlot+ interaction analysis of T130K/E52D ANT4' ligands.

| | WT Neomycin | T130K Neomycin | T130K Neomycin- AMPCPP | T130K Product state (adenylated neomycin) |
|-------------------------------------|-----------------------|------------------------|---------------------------|--|
| Resolution range¹ | 50.0-1.65 (1.71-1.65) | 51.07-1.90 (1.94-1.90) | 45.42-2.00 (2.05-2.00) | 38.58-2.50 (2.60-2.50) |
| Space group | $P2_{1}2_{1}2_{1}$ | $P2_12_12_1$ | $P2_12_12_1$ | P21 |
| Unit cell | | | | |
| a, b, c (Å) | 57.3, 97.7, 101.1 | 59.0, 97.7, 102.0 | 59.2, 98.0, 102.4 | 85.5, 59.3, 102.0 |
| α, β, γ (°) | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 94.80, 90 |
| Unique reflections | 68631 | 45570 | 40016 | 30831 |
| Multiplicity ¹ | 4.3 (4.0) | 6.5 (6.0) | 4.9 (4.6) | 3.8 (3.2) |
| Completeness (%) | 99.2 (99.8) | 97.0 (93.7) | 97.8 (95.7) | 86.6 (81.9) |
| Mean I/sigma(I) | 24.2 (1.8) | 18.5 (4.4) | 11.4 (2.7) | 12.2 (5.1) |
| Wilson B-factor | 22.2 | 24.6 | 27.8 | 25.1 |
| R-merge | 0.048 (0.481) | 0.056 (0.374) | 0.082 (0.602) | 0.077 (0.224) |
| Reflections used | 68569 | 45531 | 39968 | 30831 |
| in refinement Reflections used | 1989 | 2334 | 1984 | 1499 |
| for R-free | 1969 | 2354 | 1704 | 1477 |
| R-work | 0.173 (0.237) | 0.170 (0.203) | 0.197 (0.264) | 0.173 (0.223) |
| R-free | 0.198 (0.265) | 0.210 (0.243) | 0.229 (0.284) | 0.230 (0.305) |
| Number of non- hydrogen atoms | | | | |
| macromolecules | 4166 | 4204 | 4129 | 8110 |
| ligands | 85 | 87 | 150 | 428 |
| solvent | 557 | 387 | 368 | 217 |
| RMS(bonds) | 0.006 | 0.012 | 0.006 | 0.004 |
| RMS(angles) | 1.14 | 1.41 | 1.14 | 0.98 |
| Ramachandran favored (%) | 97.4 | 98.4 | 97.6 | 96.4 |
| Ramachandran allowed (%) | 2.4 | 1.6 | 2.4 | 3.5 |
| Ramachandran outliers (%) | 0.2 | 0.00 | 0.00 | 0.1 |
| Clashscore | 3.4 | 4.50 | 4.89 | 4.19 |
| Average B-factor | | | | |
| macromolecules | 25.8 | 26.4 | 30.6 | 29.1 |
| ligands | 31.2 | 39.9 | 36.3 | 35.3 |
| solvent | 37.6 | 34.8 | 36.1 | 25.8 |
| PDB Code | 6UN8 | 6NMK | 6NML | 6NMM |

Table S1. Data collection and refinement statistics of wild type and T130K ANT4'.

¹Number in parentheses represent values in the highest resolution shell.

| | Neomycin | Neomycin-AMPCPP | Product state (adenylated neomycin) |
|----------------------------------|------------------------|---------------------------|--|
| Resolution range ¹ | 49.22-2.30 (2.38-2.30) | 48.98 to 2.30 (2.38-2.30) | 49.65 to 2.20 (2.27-2.20) |
| Space group | $P2_{1}2_{1}2_{1}$ | $P2_{1}2_{1}2_{1}$ | P212121 |
| Unit cell | | | |
| a, b, c (Å) | 58.70, 98.45, 101.82 | 58.71, 97.95, 100.70 | 59.75, 99.30, 101.49 |
| α, β, γ (°) | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 |
| Unique reflections | 26344 | 25660 | 30558 |
| Multiplicity ¹ | 5.2 (5.0) | 3.5 (3.4) | 6.8 (6.8) |
| Completeness (%) | 98.4 (98.6) | 97.3 (95.2) | 97.6 (94.6) |
| Mean I/sigma(I) | 5.5 (5.0) | 5.8 (2.0) | 8.8 (3.9) |
| Wilson B-factor | 34.7 | 26.0 | 24.7 |
| R-merge Reflections used | 0.162 (0.644) 26263 | 0.140 (0.575) 25620 | 0.124 (0.440) 30512 |
| Reflections used for R-free | 1427 | 1396 | 1549 |
| R-work | 0.196 (0.284) | 0.180 (0.245) | 0.194 (0.239) |
| R-free | 0.235 (0.344) | 0.221 (0.313) | 0.224 (0.292) |
| Number of non- hydrogen atoms | | | |
| macromolecules | 4167 | 4098 | 4060 |
| ligands | 85 | 150 | 150 |
| solvent | 143 | 199 | 228 |
| RMS(bonds) | 0.005 | 0.010 | 0.007 |
| RMS(angles) | 1.10 | 1.38 | 1.25 |
| Ramachandran | 96.6 | 97.0 | 95.2 |
| Ramachandran allowed (%) | 3.4 | 3.0 | 4.6 |
| Ramachandran outliers (%) | 0 | 0 | 0.2 |
| Clashscore | 6.93 | 8.17 | 4.61 |
| Average B-factor | | | |
| macromolecules | 40.6 | 31.1 | 29.5 |
| ligands | 60.9 | 30.0 | 24.5 |
| solvent | 40.3 | 32.0 | 32.6 |
| PDB Code | 6PO4 | 6PO6 | 6PO8 |

Table S2. Data collection and refinement statistics of T130K/E52D ANT4'.

¹Number in parentheses represent values in the highest resolution shell.



Figure S1. Two classes of aminoglycoside antibiotics. Aminoglycoside antibiotics are grouped into two classes based on the substitution pattern of a common deoxystreptamine core. Left is the kanamycin group and right is the neomycin group. The ring nomenclature is indicated for kanamycin B and neomycin, and the 4' site of modification is circled in magenta.



Figure S2. Polder omit maps of ANT4' ligands. (A) Wild-type ANT 4' neomycin complex. (B). T130K ANT 4' neomycin complex (left), neomycin/AMPCPP ternary complex (center) and AMP-neomycin/pyrophosphate ternary complex. (C) T130K/E52D ANT 4' neomycin complex (left), neomycin/AMPCPP ternary complex (center) and AMP-neomycin/pyrophosphate ternary complex. Polder maps are contoured at 3 sigma.



Figure S3. LigPlot+ diagram of T130K ANT4' ligands. (A) Neomycin. (B) Neomycin and AMPCPP. (C) AMPneomycin and pyrophosphate.



Figure S4. LigPlot+ diagram of T130K/E52D ANT4' ligands. (A) Neomycin. (B) Neomycin and AMPCPP. (C) AMP-neomycin and pyrophosphate.



Figure S5. Additional adenylated neomycin in T130K ANT4' structure. The second adenylated neomycin product (Neo-AMP2) binds directly to the adenylated neomycin in the active site (Neo-AMP1) and both monomers of ANT4'. Hydrogen bonds are represented as black dashed lines. The protein monomers are colored blue and cyan. The adenylated neomycin in the active site is colored magenta and yellow, whereas the second product state outside of the active site is colored magenta and green.



Figure S6. Thermodynamic parameters for the binding of neomycin to T130K and T130K/E52D ANT4' using ITC.